ImmuneBridge is developing allogeneic cell therapies using proprietary expansion technology to amplify cord blood-derived immune stem cells while preserving their immune multipotency. This approach aims to provide a consistent and abundant cellular source for immunotherapies, making effective cancer treatments more accessible to patients.
Funding
$20.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MVFounders
Product
Problem
Allogeneic cell therapies face challenges in obtaining a consistent and scalable source of immune cells, hindering their widespread application in cancer treatment. Traditional methods of cell sourcing and expansion may compromise the cells' multipotency, limiting their therapeutic efficacy.
Solution
ImmuneBridge is developing off-the-shelf allogeneic cell therapies derived from cord blood using a proprietary expansion technology. This technology amplifies immune stem cells while preserving their full immune multipotency, creating a consistent, diverse, and abundant source of cells for immunotherapy. By leveraging this approach, ImmuneBridge aims to make effective and accessible cancer treatments available to a broader patient population.
Target Audience
The primary target audience includes oncology centers, hospitals, and clinicians seeking readily available and effective allogeneic cell therapies for cancer patients.
Features
- Proprietary expansion technology for amplifying cord blood-derived immune stem cells
- Preservation of full immune multipotency during cell expansion
- Consistent and abundant source of cells for allogeneic cell therapies
- Off-the-shelf availability for immediate patient treatment